- Home
- Companies
- Mersana Therapeutics
- Products
- Upifitamab Rilsodotin (UpRi)
Upifitamab Rilsodotin (UpRi)
UpRi, a first-in-class ADC targeting the sodium-dependent phosphate transport protein NaPi2b, utilizes the Dolaflexin platform to deliver about 10 DolaLock payload molecules per antibody. The NaPi2b antigen is broadly expressed in ovarian cancer and non-small cell lung cancer (NSCLC) adenocarcinoma. UpRi is being studied in UPLIFT, a single-arm registration strategy, in patients with platinum-resistant ovarian cancer as well as the expansion portion of a Phase 1 proof-of-concept clinical study in patients with NSCLC adenocarcinoma.
Data from the dose escalation portion of the UpRi Phase 1 study were presented in March 2020 and showed encouraging clinical activity with confirmed responses and prolonged stable disease in heavily pretreated patients, without pre-selection for NaPi2b expression. These data showed that UpRi was well-tolerated without the severe toxicities commonly seen with other ADCs such as neutropenia, ocular toxicities, or peripheral neuropathy.
Interim data from the expansion portion of the UpRi Phase 1 study were presented at the ASCO virtual meeting in May 2020. Updated interim data from the ovarian cancer cohort of the UpRi Phase 1 Expansion Study were presented at the ESMO virtual meeting in September 2020. These data showed promising anti-tumor activity with confirmed complete responses, partial responses and durable stable disease in platinum-resistant ovarian cancer patients and a safety profile consistent with previously reported dose escalation data with no new safety signals observed.
In August 2020, the U.S. Food and Drug Administration (FDA) granted Fast Track Designation for XMT-1536, for the treatment of patients with platinum-resistant high-grade serous ovarian cancer who have received up to three prior lines of systemic therapy or patients who have received four prior lines of systemic therapy regardless of platinum status.
We are enrolling platinum-resistant ovarian cancer patients in UPLIFT and continue to enroll NSCLC adenocarcinoma patients in the expansion portion of the Phase 1 study.